Noah Rosenberg takes chief medical officer role at Esperion

Will develop and manage the firm’s clinical programmes

Noah Rosenberg has taken over as chief medical officer (CMO) at Esperion Therapeutics and will lead the Esperion clinical advisory board and develop and manage the company's clinical programmes. He will also manage the regulatory review process for the company's investigational therapies to treat cardiovascular and metabolic diseases.

Over the past decade, Dr Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, Sanofi and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute, he led the in-licensing of the GK1-399 programme.

‘Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,’ Dr Rosenberg said.

You may also like

Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Subscribe now